Post Archive by Day

Olpasiran leads to significant and sustained reduction in OxPL on apolipoprotein B

Lower risk for COPD exacerbations seen with SGLT-2 inhibitors and GLP-1 receptor agonists, but not with DPP-4 inhibitors

Although screening rates are higher for exposed individuals, rates are low in both exposed and unexposed individuals

Almost all older adults in SPRINT trial have predicted net benefit favoring systolic BP target <120 mm Hg versus <140 mm Hg

Women with APO and their APO-free sisters both have increased risks relative to unrelated APO-free comparators